Douglas Tsao: Okay. Great. And maybe a follow-up question on the UDENYCA franchise, I’m just curious, we’re starting to see uptake of both of your on-boxes device as well as the auto-injector. I’m just curious if you have any insight in terms of how physicians are using the 2 — those 2 dosage forms or product types. Are there sort of themes in terms of the types of patients that are getting the on-body versus the auto-injector and vice versa? Thank you.
Denny Lanfear: Paul, I guess, the question is, what sort of patient settings would they go for the auto-injector with patients settings for the on body and so on?
Paul Reider: Yes, Doug. So let me frame this in a couple of different ways. First, let’s take the clinics. So the clinic segments are going to gear more towards all 3 of the presentations because they have patients who like to come back to the office the next day. They like the high-touch connectivity with their nurse and with their doctor. And so therefore, the prefilled syringe or the auto-injector are positioned for those patients. But some patients in the clinic, they want their injection experience at home. Therefore, we give them the option of the on-body device with a well-designed 5-minute injection. But if the patient wants to self-inject, and not aware of the device, they can choose the auto-injector and under 10 seconds inject themselves at the time and place that they like.
So that’s really how we’re positioning by the patients and by the provider. The hospitals, they tend to go a little bit more with the on-body device or the prefilled syringe. So we’ve had good uptake with auto-injector in the hospital, but not nearly as much in the clinic because they prefer either the prefilled syringe or the on-body is the at-home reference. So that’s kind of how we’re seeing it. And again, being the only franchise with all three options really sets us apart from a competitive differentiation. And I think you see that in our market share growth.
Douglas Tsao: Great. Thanks.
Operator: Question comes from the line of Colleen Kusy with Baird. Your line is open.
Colleen Kusy: Thanks. Good afternoon and thanks for taking our questions. So for realizing you’re not providing guidance at this point, but how to think about what the growth drivers for UDENYCA will be in 2024? Is it growing the on-body? Is it just focusing on the prefilled syringe and auto-injectors kind of thoughts around growth for UDENYCA this year? And then sorry if I missed this in the prepared remarks, but if you could just speak towards the potential of reaching cash flow positivity and if that goal is still set for 2024. Thank you.
Denny Lanfear: Thank you, Colleen. I’ll let Paul handle the growth drivers for UDENYCA first, and then I’ll handle your secondary question with respect to 2024. Paul?
Paul Reider: Yes, thanks for your question. Yes, I think we fully expect the on-body to be the predominant driver of our growth in 2024. As Denny mentioned that the approval of that product now opens up segments of the market that have been difficult to penetrate with our prefilled syringe and auto injectors. So we’re really looking for that SKU, that presentation to drive market share growth for the remainder of the year. It will be buoyed and facilitated by our payer coverage, which I mentioned was doubled this year versus last year and that payer coverage extends to all three product presentations. So, really not inhibited by payer coverage by each of those presentations. So, where we’ve got it. We’ve got all three, and we will leverage that as we continue to execute.
Denny Lanfear: Thanks, Paul. With respect to your secondary question, I would first say with 2024 is shaping up to be a more predictable year than 2023. And so far as we had to focus a lot on getting approvals. We focused on getting the on-body approval. We did it successfully. We went and got LOQTORZI approved and the FDA that was — that took a little time. We got that done. And then we rolled into the launches, particularly the launch of the on-body the launch of the auto-injector and now launch like LOQTORZI. So the trajectory over 2024 is continued revenue growth. We’ll see more like LOQTORZI as we go on the year — quarter. And we believe that we’ll also see continued growth with respect to UDENYCA for the reasons that Paul just laid out.
The issue is like how steep will that growth curve be, how much growth. And what we are constrained by is the real world looking experience, looking backward trying — we are very early in these launches. We have just gotten out there. With respect to LOQTORZI, we’re making very good progress on the formularies, but it’s a rare disease. Now we have to acquire the patients and so on. But I think we’re off to a very good start. So we don’t want to forecast with respect to our forward looking, although clearly, as I indicated, growth will continue. So it’s a question of when and how that will go up, that remains very clearly in our sights is to move forward in that direction. But the growth is something that we’re happy with.
Colleen Kusy: Great. Thanks for taking our questions.
Denny Lanfear: Thank you, Colleen.
Operator: There are no further questions at this time. Mr. Denny Lanfear, I turn the call back over to you.
Denny Lanfear: Thank you, operator. Thank you all for joining us on call today, and thank you for the opportunity to enumerate for you the progress we’ve made across all of our key overtures, particularly with respect to driving our sales and advancing our tumor microenvironment focused pipeline, and we look forward to pricing you of our progress at our next call. Thank you.
Operator: Today’s conference call. You may now disconnect.
